In AD, the core cerebrospinal fluid (CSF) biomarkers Aβ (specifically the 42 amino acid long variant (Aβ1–42)), total tau protein (T-tau), and P-tau [27] have been shown to be potent in discriminating subjects with AD from controls and identify subjects with prodromal AD [28]. The gene discussed is MAPT; the disease is Alzheimer disease.